Biotech
4D Molecular Therapeutics
4D Molecular Therapeutics raises $105M Series D at $800M valuation
$105M
Total Raised
Series D
Latest Round
2013
Founded
200+
Employees
5858 Horton Street, Emeryville, CA 94608
1 min read
Quick Facts
Valuation
$800M
Latest Round Size
$105M
Latest Round Date
May 2024
4D Molecular Therapeutics: Series D Funding Round
4D Molecular Therapeutics has successfully raised $105M in Series D funding, reaching a valuation of $800M.
Company Overview
Targeted gene therapy vectors
Funding Details
The Series D round was led by Versant Ventures, with participation from Foresite Capital, Viking Global Investors, Fidelity.
Company Information
- Headquarters: 5858 Horton Street, Emeryville, CA 94608
- Founded: 2013
- Employees: 200+
- Category: Biotech
Investment
4D Molecular Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Versant Ventures: Verified investor in Series D
- Foresite Capital: Verified investor in Series D
- Viking Global Investors: Verified investor in Series D
- Fidelity: Verified investor in Series D
Key Investors
Versant Ventures
Lead Investor
Verified investor in Series D
Foresite Capital
Investor
Verified investor in Series D
Viking Global Investors
Investor
Verified investor in Series D
Fidelity
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M